Arecor Limited has presented positive results for the Phase I clinical trial of its ultra-rapid acting insulin product candidate, AT247, to the American Diabetes Association 80th Scientific Sessions (ADA) virtual meeting.
“AT247 has clearly demonstrated faster insulin absorption with an accelerated Pharmacokinetic (PK) and Pharmacodynamic (PD) profile compared to NovoRapid and Fiasp,” Professor Thomas Pieber, the principal investigator for the study said, Arecor noted in a statement.
WATCH: Arecor CEO updates as data for lead insulin product is presented at American Diabetes Association
Pieber added: "AT247 has the potential to significantly improve postprandial glucose control and flexibility of insulin dosing as well as the potential clinical benefits of avoiding both hypo and hyperglycaemia."
Arecor pointed out that AT247 has been formulated to accelerate insulin absorption, post-injection, to enable more effective management of blood glucose levels.
It said the next step will be to explore AT247’s potential as the ideal insulin for use in a pump and fully closed-loop delivery (artificial pancreas) systems.
Current best-in-class insulins are simply not fast enough acting to adequately control blood glucose within the artificial pancreas system around mealtimes.
Sarah Howell, Arecor's chief executive noted that successful completion of the phase 1 study was an important landmark for AT247.
“AT247 is under development as ultra-rapid acting insulin targeted at improving treatment and healthcare outcomes for people living with Type I diabetes. In addition to the potential to improve postprandial blood glucose control, AT247 may play a critical role in advancing artificial pancreas systems.
“With AT247’s favourable profile over current treatments, we believe that our product has the potential to advance the diabetes treatment landscape,” she said in the company's statement